Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency.
CVID
adjuvanted QIV
azoximer bromide
immunogenicity
influenza
seropositive/seronegative
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
02 Nov 2020
02 Nov 2020
Historique:
received:
26
06
2020
revised:
12
09
2020
accepted:
30
09
2020
entrez:
5
11
2020
pubmed:
6
11
2020
medline:
6
11
2020
Statut:
epublish
Résumé
Influenza prophylaxis with the use of quadrivalent vaccines (QIV) is increasingly being introduced into healthcare practice. In total, 32 healthy adults and 6 patients with common variable immunodeficiency (CVID) received adjuvant QIV during 2018-2019 influenza season. Depending on initial antibody titers, healthy volunteers were divided into seronegative (≤1:20) and seropositive (≥1:40). To evaluate immunogenicity hemagglutination inhibition assay was used. All participants completed the study without developing serious post-vaccination reactions. Analysis of antibody titer 3 weeks after immunization in healthy participants showed that seroprotection, seroconversion levels, GMR and GMT for strains A/H1N1, A/H3N2 and B/Colorado, B/Phuket among initially seronegative and seropositive participants meet the criterion of CHMP effectiveness. CVID patients showed increase in post-vaccination antibody titer without reaching conditionally protective antibody levels. Adjuvant QIV promotes formation of specific immunity to vaccine strains, regardless of antibodies' presence or absence before. In CVID patients search of new regimens should be continued.
Sections du résumé
BACKGROUND
BACKGROUND
Influenza prophylaxis with the use of quadrivalent vaccines (QIV) is increasingly being introduced into healthcare practice.
METHODS
METHODS
In total, 32 healthy adults and 6 patients with common variable immunodeficiency (CVID) received adjuvant QIV during 2018-2019 influenza season. Depending on initial antibody titers, healthy volunteers were divided into seronegative (≤1:20) and seropositive (≥1:40). To evaluate immunogenicity hemagglutination inhibition assay was used.
RESULTS
RESULTS
All participants completed the study without developing serious post-vaccination reactions. Analysis of antibody titer 3 weeks after immunization in healthy participants showed that seroprotection, seroconversion levels, GMR and GMT for strains A/H1N1, A/H3N2 and B/Colorado, B/Phuket among initially seronegative and seropositive participants meet the criterion of CHMP effectiveness. CVID patients showed increase in post-vaccination antibody titer without reaching conditionally protective antibody levels.
CONCLUSION
CONCLUSIONS
Adjuvant QIV promotes formation of specific immunity to vaccine strains, regardless of antibodies' presence or absence before. In CVID patients search of new regimens should be continued.
Identifiants
pubmed: 33147763
pii: vaccines8040640
doi: 10.3390/vaccines8040640
pmc: PMC7712402
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Vaccine. 2020 Mar 30;38(15):3121-3128
pubmed: 32145994
Vaccine. 2013 Jan 21;31(5):770-6
pubmed: 23228813
Clin Infect Dis. 2020 Oct 23;71(7):1704-1714
pubmed: 31828291
Zh Mikrobiol Epidemiol Immunobiol. 2016 Nov;(6):61-65
pubmed: 30695391
Front Immunol. 2019 Nov 28;10:2693
pubmed: 31849934
Vaccine. 2020 Jan 10;38(2):242-250
pubmed: 31635976
Clin Infect Dis. 2011 Jan 15;52(2):248-56
pubmed: 21288852
Clin Immunol. 2010 Aug;136(2):228-35
pubmed: 20421178
Vaccine. 2010 Feb 25;28(9):2149-56
pubmed: 20003926
Vaccine. 2013 Nov 12;31(47):5572-8
pubmed: 24016810
Clin Exp Immunol. 1998 Jan;111(1):70-5
pubmed: 9472663
BMC Infect Dis. 2013 Jul 24;13:343
pubmed: 23883186
Vaccine. 2016 May 5;34(21):2417-2423
pubmed: 27055021
Scand J Immunol. 2011 Aug;74(2):210-8
pubmed: 21438900
J Allergy Clin Immunol. 2018 Dec;142(6):1922-1931.e2
pubmed: 29678747
Zh Mikrobiol Epidemiol Immunobiol. 2016 Sep;(5):23-28
pubmed: 30695345
Clin Immunol. 2011 Nov;141(2):161-8
pubmed: 21889412
Hum Vaccin Immunother. 2012 Jan;8(1):81-8
pubmed: 22252006
BMC Infect Dis. 2009 Jan 17;9:2
pubmed: 19149900
Vaccine. 2014 Mar 14;32(13):1480-7
pubmed: 24486352
Hum Vaccin Immunother. 2014;10(1):92-9
pubmed: 24047817
Vaccine. 2017 Apr 4;35(15):1856-1864
pubmed: 28302411
Influenza Other Respir Viruses. 2015 Aug;9 Suppl 1:3-12
pubmed: 26256290